Evidence map›Paper›PMID 31645416›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2019

STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.

Uri Rozovski, David M Harris, Ping Li, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan A Burger, Prithviraj Bose, Phillip A Thompson, Nitin Jain and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. WNT signaling and cancer stemness.Essays in biochemistry · 2022
    Article
  6. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Uri RozovskiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
David M HarrisDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Ping LiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0002-0195-0871
Zhiming LiuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Preetesh JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Alessandra FerrajoliDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Jan A BurgerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Prithviraj BoseDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0002-4343-5712
Phillip A ThompsonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0003-2086-6031
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
William G WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Orit UzielThe Felsenstein Medical Research Center, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0001-8613-121X
Michael J KeatingDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0002-9121-6450
Zeev EstrovDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; zestrov@mdanderson.org.ORCID 0000-0002-1623-3613
The University of Texas MD Anderson Cancer Center · USTel Aviv University · IL

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

The wingless and integration site growth factor-5a (Wnt5a) is a ligand of the receptor tyrosine kinase-like orphan receptor-1 (ROR1). Because both Wnt5a and ROR1 are expressed in circulating chronic lymphocytic leukemia (CLL) cells, and because in other cell types, STAT3, which is constitutively activated in CLL, induces Wnt5a signaling, we wondered whether STAT3 induces the expression of Wnt5a in CLL cells. Sequence analysis detected four putative STAT3 binding sites in close proximity to the Wnt5a gene promoter's start codon. Chromatin immunoprecipitation and EMSA revealed that STAT3 binds to the Wnt5a gene promoter, and a luciferase assay showed that STAT3 activates the Wnt5a gene. Additionally, transfection of peripheral blood CLL cells with STAT3 short hairpin RNA downregulated Wnt5a mRNA and protein levels, suggesting that STAT3 binds to the Wnt5a gene promoter and induces the expression of Wnt5a in CLL cells. Flow cytometry and confocal microscopy determined that both Wnt5a and its receptor ROR1 are coexpressed on the surface of CLL cells, and Western immunoblotting showed an inverse correlation between Wnt5a and ROR1 protein levels, implying that, regardless of CLL cells' ROR1 levels, blocking the interaction between Wnt5a and ROR1 might be beneficial to patients with CLL. Indeed, transfection of CLL cells with Wnt5a small interfering RNA reduced Wnt5a mRNA and protein levels and significantly increased the spontaneous apoptotic rate of CLL cells. Taken together, our data unravel an autonomous STAT3-driven prosurvival circuit that provides circulating CLL cells with a microenvironment-independent survival advantage.

Indexed as

Cell SurvivalHumansLeukemia, Lymphocytic, Chronic, B-CellProtein BindingSignal TransductionSTAT3 Transcription FactorWnt-5a ProteinSTAT3 protein, humanSTAT3 Transcription FactorWnt-5a ProteinWNT5A protein, human

Identifiers

PMID31645416
PMCPMC6864283
OpenAlexW2981347128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.